Co-inhibitory Immune Checkpoints in Oral Squamous Cell Carcinoma

doi:10.13701/j.cnki.kqyxyj.2019.12.001

Abstract

Abstract: Clinical breakthroughs have been made in the treatment of cancer by immune checkpoint, especially by the antibody of PD-1.However, there are still many cancer patients who are not responsive to immune checkpoint blockade. Therefore, it is necessary to further study the mechanism of immune checkpoint, which could be exploited for oral squamous cell carcinoma (OSCC). In this review, we summarize the expression and the mechanism of partial co-inhibitory immune checkpoint molecules and discuss the possibility of targeting co-inhibitory immune checkpoints for the treatment of OSCC.

Key words: oral squamous cell carcinoma, immune checkpoint, immune escape

SUN Zhijun, WU Lei. Co-inhibitory Immune Checkpoints in Oral Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2019, 35(12): 1107-1110.

References

[1] Ferris RL. Immunology and immunotherapy of head and neck cancer [J]. J Clin Oncol, 2015, 33(29): 3293-3304.
[2] Dogan V, Rieckmann T, Munscher A, et al. Current studies of immunotherapy in head and neck cancer [J]. Clin Otolaryngol, 2018, 43(1): 13-21.
[3] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy [J]. Nat Rev Cancer, 2012, 12(4): 252-264.
[4] Sharma P, Allison JP. The future of immune checkpoint therapy [J]. Science, 2015, 348(6230):56-61.
[5] Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial [J]. Lancet Oncol, 2016, 17(7): 956-965.
[6] Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck [J]. N Engl J Med, 2016, 375(19): 1856-1867.
[7] Yu GT, Bu LL, Huang CF, et al. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPalpha axis in HPV negative head and neck squamous cell carcinoma [J]. Oncotarget, 2015, 6(39): 42067-42080.
[8] Malm IJ, Bruno TC, Fu J, et al. Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma [J]. Head Neck, 2015, 37(8): 1088-1095.
[9] Jie HB, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients [J]. Br J Cancer, 2013, 109(10): 2629-2635.
[10] Adelstein D, Gillison ML, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 2.2017 [J]. J Natl Compr Canc Netw, 2017, 15(6): 761-770.
[11] Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition [J]. N Engl J Med, 2017, 377(25): 2500-2501.
[12] Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma [J]. Cancer Res, 2013, 73(6): 1733-1741.
[13] Kim HR, Ha SJ, Hong MH, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients [J]. Sci Rep, 2016, 6: 36956.
[14] Ock CY, Kim S, Keam B, et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma [J]. Oncotarget, 2016, 7(13): 15901-15914.
[15] Yu GT, Bu LL, Zhao YY, et al. CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma [J]. Oncoimmunology, 2016, 5(6): e1151594.
[16] Clavijo PE, Moore EC, Chen J, et al. Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells [J]. Oncotarget, 2017, 8:55804-55820.
[17] Strauss L, Bergmann C, Gooding W, et al. The frequency and suppressor function of CD4⁺CD25^highFoxp3⁺ T cells in the circulation of patients with squamous cell carcinoma of the head and neck [J]. Clin Cancer Res, 2007, 13(21): 6301-6311.
[18] Deng WW, Mao L, Yu GT, et al. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma [J]. Oncoimmunology, 2016, 5(11): e1239005.
[19] Xu F, Liu J, Liu D, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses [J]. Cancer Res, 2014, 74(13): 3418-3428.
[20] Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8⁺ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia [J]. Blood, 2011, 117(17): 4501-4510.
[21] Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints [J]. Nat Commun, 2016, 7: 10501.
[22] Liu JF, Ma S R, Mao L, et al. T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer [J]. Mol Oncol, 2017, 11(2): 235-247.
[23] Wu L, Deng WW, Yu GT, et al. B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma [J]. Cancer Immunol Immunother, 2016, 65(9): 1035-1045.
[24] Li J, Lee Y, Li Y, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8⁺ T cells [J]. Immunity, 2018, 48(4): 773-786.
[25] Lines JL, Pantazi E, Mak J, et al. VISTA is an immune checkpoint molecule for human T cells [J]. Cancer Res, 2014, 74(7): 1924-1932.
[26] Blando J, Sharma A, Higa MG, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer [J]. Proc Natl Acad Sci U S A, 2019, 116(5): 1692-1697.
[27] Gao J, Ward JF, Pettaway CA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer [J]. Nat Med, 2017, 23(5): 551-555.
[28] Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity [J]. Nat Immunol, 2018, 19(7): 723-732.
[29] Wu L, Mao L, Liu JF, et al. Blockade of TIGIT/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma [J]. Cancer Immunol Res, 2019, 7(10):1700-1713.